Tarsus Pharmaceuticals (NasdaqGS:TARS) FY Conference Transcript

Tarsus Pharmaceuticals FY Conference Summary Company Overview - Tarsus Pharmaceuticals is a Southern California-based company focused on pioneering new categories in eye care, particularly with its flagship product XDEMVY, which targets Demodex blepharitis, a condition affecting approximately 25 million Americans [2][3]. Financial Performance - Tarsus reported over $450 million in revenue in the second year of XDEMVY's launch, positioning it on a path to become a blockbuster with peak sales projected to exceed $2 billion [3][6]. - The company anticipates achieving this peak sales figure with less than 10% market penetration of the estimated 25 million patients suffering from demodicosis [12]. Product Pipeline - Tarsus is developing additional products, including: - TP-04: A candidate for treating Ocular Rosacea, currently in Phase 2 trials, addressing a significant unmet need with no approved therapies available [4][56]. - TP-05: A prophylactic treatment for Lyme disease, showing promising Phase IIa data with a 95% tick kill rate within 24 hours [5][66]. Market Dynamics and Growth Strategy - The company has successfully educated over 20,000 doctors about XDEMVY, with a strategy focused on increasing prescribing frequency from monthly to daily [25][27]. - Tarsus has invested approximately $80 million in direct-to-consumer advertising, significantly raising awareness of Demodex blepharitis from 0% to 25% among patients [32][33]. - The company has achieved 90% payer coverage, ensuring broad access to XDEMVY for patients [37]. Sales Guidance and Market Expectations - Tarsus provided sales guidance for the upcoming year, projecting revenue between $670 million and $700 million, with expectations of 50% growth [40][48]. - The company anticipates a flat to slightly down revenue in Q1 due to seasonal factors affecting patient visits [49][51]. Clinical Insights and Physician Feedback - Feedback from physicians indicates a strong belief in XDEMVY's efficacy, with many doctors surprised by the low number of treated patients compared to the potential market size [9][10]. - The company is focused on demonstrating proof of concept for TP-04 and TP-05, with expected data readouts in the first half of 2027 [59][68]. Strategic Expansion - Tarsus is exploring opportunities to expand its pipeline, focusing on category-creating products in the anterior segment of the eye, with plans to eventually move into retinal diseases [74][76]. - The company aims to leverage its strong sales force to introduce new products effectively and maintain growth momentum [72][79]. Conclusion - Tarsus Pharmaceuticals is positioned for significant growth with its innovative approach to eye care, a strong product pipeline, and effective market strategies. The company is focused on addressing unmet medical needs and expanding its market presence through education and awareness initiatives.